Macrolides for diffuse panbronchiolitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 1, 2015, Pages

  Lin, Xiufang ^a   Lu, Jing ^a   Yang, Ming ^a   Dong, Bi Rong ^a   Wu, Hong Mei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT;

BRONCHIOLITIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DIFFUSE PANBRONCHIOLITIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM CARE; LUNG FUNCTION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; DIAGNOSTIC IMAGING; HAEMOPHILUS INFECTIONS; X-RAY COMPUTED TOMOGRAPHY;

ANTI-BACTERIAL AGENTS; BRONCHIOLITIS; ERYTHROMYCIN; HAEMOPHILUS INFECTIONS; HUMANS; MACROLIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85009769108     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007716.pub4     Document Type: Review

References (49)

1. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology 1993;189:559-62.
2. Hyeon KC, Jung KW, Hun JS, Gyu YC, Whan KY, Seog HD, et al.Long-term follow-up of patients with diffuse panbronchiolitis after erythromycin therapy. Journal of Korea Medical Science 1997;53:414-9.
3. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, et al.Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respiratory Medicine 2003;97:844-50.
4. Kadota J-I, Mukae H, Tomono K, Kohno S, Nasu M. Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases. International Journal of Antimicrobial Agents 2004;24:550-4.
5. Kadota J-I, Mukae H, Mizunoe S, Kishi K, Tokimatsu I, Nagai H, et al.Long-term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Internal Medicine 2005;44:200-6.
6. Kudoh S, Kimura H, Uetake M, Hirayama T, Hisaya K, Teratani Y, et al.Clinical effect of low-dose long-term administration of macrolides on diffuse panbronchiolitis. Japanese Journal of Thoracic Disease 1984;22(Suppl):254.
7. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. American Journal of Respiratory and Critical Care Medicine 1998;157:1829-32.
8. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145-9.
9. Sato A, Hayakawa H, Suda T. Ofloxacin and erythromycin in the management of diffuse panbronchiolitis. Drugs 1993:399-400.
10. Shirai R, Abe K, Yoshinaga M, Ishimatsu Y, Matsubara Y, Kawakami K, et al.Analysis of cases allowed to cease erythromycin therapy for diffuse panbronchiolitis - comparative study between patients with cessation of the therapy and patients continuing the therapy. Journal of the Japanese Association for Infectious Diseases 1997;71:1155-61.
11. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long-term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Japanese Journal of Thoracic Diseases 1990;28:1305-13.
12. Yamamoto M. Therapeutic effects of erythromycin on diffuse panbronchiolitis. A multicenter, double blind placebo-controlled trial. Sarcoidosis 1992;Suppl 1:633-6.
13. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology 2006;11:249-61.
14. Bai H, Zhao J, Liao M. Diffuse panbronchiolitis: a case report. Chinese Journal of Practical Internal Medicine 2000;20(3):162.
15. Chen BZ, Xiang XD, Chen P. A case of diffuse panbronchiolitis. Bulletin of Hunan Medical University 2000;25(6):534.
16. Chen X, Liu S, Wang J, Ni Y. Diffuse panbronchiolitis: six cases report. Fujian Medical Journal 2007;29(6):42-3.
17. Desai SJ, Gephardt GN, Stoller JK. Diffuse panbronchiolitis preceding ulcerative colitis. Chest 1989;95:1342-4.
18. Ding K, Liu M-B, Wu JL, Ma H-Q, Fang X-Y, Miao GB, et al.Diffuse panbronchiolitis in China: analysis of 45 cases. Chinese Medical Journal 2007;120:2046-8.
19. Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. American Journal of Respiratory and Critical Care Medicine 1996;154:497-503.
20. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. International Journal of Antimicrobial Agents 2008;31:12-20.
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al.Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983;83:63-9.
23. Hou X, Yuan X, Chen L. Diffuse panbronchiolitis: a case report. Journal of Yunyang Medical College 1998;17(2):106.
24. Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chinese Medical Journal 1996;109(12):949-52.
25. Hu S, Luo Y. Diffuse panbronchiolitis: a case report and review of the literature. Jiangxi Medical Journal 2009;44(2):137-9.
26. Izumi T, Doi O, Nobechi A, Homma Y, Kino N, Nakata K, et al.Nation-wide survey of diffuse panbronchiolitis. Annual report on the study of interstitial lung disease in 1982. Grant-in Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1983:3-41.
27. Izumi T. Diffuse panbronchiolitis. Chest 1991;100:596-7.
28. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, et al.Study on azithromycin in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1995;69:711-22.
29. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, et al.Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Japanese Journal of Thoracic Diseases 1987;25:632-42.
30. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Li H, Huang J, Li X, Yu H, Zhao L, He G. Clinical analysis of twenty four patients with diffuse panbronchiolitis. Suzhou University Journal of Medical Science 2007;27(3):449-52.
32. Liu Y, Hu H, Zhang J. A clinical trial of 14 and 15 membered macrolides in treating six cases of diffuse panbronchiolitis. Chinese Journal of Internal Medicine 1999;38(9):622-4.
33. Liu M, Ding K, Wu J, Ma H, Fang X, Miao G, et al.Analysis of 45 patients with diffuse panbronchiolitis in China. Chinese Journal of Medicine 2006;41(11):39-40.
34. López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Current Opinion in Pharmacology 2008;8:286-91.
35. Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al.Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. European Respiratory Journal 1999;13:1371-9.
36. Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB. Annual report on the study of diffuse lung disease in 1999. Grant-in aid from the Ministry of Health and Welfare of Japan. Tokyo, 2000:111.
37. Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian. Chest 1990;98:515-6.
38. Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America. Report of three cases and review of the literature. American Journal of Surgical Pathology 1991;15:43-7.
39. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
40. Sandrini A, Balter MS, Chapman KR. Diffuse panbronchiolitis in a Caucasian man in Canada. Canadian Respiratory Journal 2003;10:449-51.
41. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrobial Agents and Chemotherapy 1995;39:1688-90.
42. Tan T, Liu W, Jiang L. Clinical analysis of 43 cases of diffuse panbronchiolitis. China Journal of Modern Medicine 2006;16:2538-9.
43. Xue F, Mi J. Diffuse panbronchiolitis: a case report. Shanxi Medical Journal 2002;31(3):278.
44. Yamamoto M, Kudoh S, Ina Y, Tamura A. Clinical efficacy of erythromycin for patients with diffuse panbronchiolitis - a double blind study. Saishin Igaku 1990;45:103-8.
45. Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969;23:442-51.
46. Zai H, Huo Z. Clinical analysis of twenty three patients with diffuse panbronchiolitis. Clinical Medicine of China 2009;25(1):51-4.
47. Yang M, Dong BR, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007716]
48. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007716.pub2]
49. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007716.pub3]